Acarix AB logo

Acarix AB (7AC)

Market Closed
7 Aug, 20:00
XFRA XFRA
0. 02
-0
-1.2987%
27.87M Market Cap
- P/E Ratio
- Div Yield
5,000 Volume
- Eps
0.02
Previous Close
Add Transaction
Day Range
0.02 0.02
Year Range
0.01 0.04
Want to track 7AC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

7AC closed Friday lower at €0.02, a decrease of -1.2987% from Thursday's close, completing a monthly decrease of -1.2987% or €0. Over the past 12 months, 7AC stock lost -12.1387%.
7AC is not paying dividends to its shareholders.
The last earnings report, released on May 11, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XSTO (SEK).

7AC Chart

People also search for

DCV
Advanex Inc.
13.5
-11.1842%
OKYO Pharma Limited
1.36
0%
78W
Modulight Oyj
1.05
+0.9569%
3NQ
Nano mRNA Co., Ltd.
0.55
+1.8518%
PGT
StrongPoint ASA
0.84
+0.2375%

Acarix AB (7AC) FAQ

What is the stock price today?

The current price is €0.02.

On which exchange is it traded?

Acarix AB is listed on XFRA.

What is its stock symbol?

The ticker symbol is 7AC.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 27.87M.

Has Acarix AB ever had a stock split?

No, there has never been a stock split.

Acarix AB Profile

Health Care Technology Industry
Healthcare Sector
Aamir Mahmood CEO
XFRA Exchange
SE0009268717 ISIN
SE Country
8 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Acarix AB (publ) is a pioneering medical device company founded in 2009, with its headquarters situated in Malmö, Sweden. It focuses on the development of innovative solutions designed for the rapid rule-out of coronary artery disease (CAD) using advanced AI technologies. The company has established itself in the global market by offering its state-of-the-art diagnostic aids in countries across the Nordic region, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. Acarix AB leverages sensitive acoustics and sophisticated computational processing to enhance the accuracy and efficiency of CAD diagnosis, aiming to improve patient outcomes and streamline healthcare processes.

Products and Services

  • CADScor System
  • This innovative point-of-care diagnostic aid is at the forefront of Acarix AB's product lineup. The CADScor System utilizes the company's groundbreaking technology to analyze the acoustics of coronary blood flow, combined with advanced computational processing. Its primary use is in the rapid rule-out of coronary artery disease (CAD), offering clinicians a non-invasive, highly sensitive tool for assessing patients. By employing this system, healthcare practitioners can quickly identify patients who may need further cardiovascular diagnostic assessments, thereby optimizing the care pathway and reducing unnecessary hospital referrals and diagnostics.

Contact Information

Address: World Trade Center
Phone: +45 44 41 44 41